Moreover, cross-resistance to diverse TKIs has been reported [81], and HER2 L755S mutation, although infrequent in breast cancer, can make tumors insensitive to lapatinib, neratinib, and tucatinib [82]. Here, ERBB2 is linked to breast carcinoma.